{"id":"W2898220308","doi":"10.1093/annonc/mdy292.064","title":"Afatinib versus erlotinib as second-line treatment of patients (pts) with advanced lung squamous cell carcinoma (SCC): Final analysis of the global phase III LUX-Lung 8 (LL8) trial","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Afatinib; Erlotinib; Oncology; Internal medicine; Squamous-cell carcinoma of the lung; Lung; Phases of clinical research; Basal cell; Clinical trial; Epidermal growth factor receptor; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002324428,0.001298096,0.001925279,0.0003203569,0.0002250311,0.001150318,0.0007411644,0.001097081,0.004230346],"category_scores_gemma":[0.001712235,0.0003831561,0.002660094,0.000379309,0.0007380824,0.001083991,0.0005101635,0.00268713,0.0008742573],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009679243,"about_ca_system_score_gemma":0.0008724719,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005471506,"about_ca_topic_score_gemma":0.002414524,"domain_scores_codex":[0.9993057,0.0004291368,0.00004446816,0.00008981214,0.0000428126,0.00008806721],"domain_scores_gemma":[0.9993169,0.0001556332,0.0001961305,0.00004629057,0.00004795039,0.0002370438],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9271433,0.004992477,0.002784463,0.001497353,0.003169975,0.00008517856,0.0001238783,0.001609343,0.00517296,0.000199623,0.003048134,0.05017339],"study_design_scores_gemma":[0.8755574,0.1125916,0.005786923,0.00008670005,0.001581579,0.0001876844,0.00005107011,0.0008720959,0.0007738464,0.0003560503,0.002128474,0.00002661192],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9822471,0.008796621,0.0006634338,0.00124018,0.0003436862,0.001984521,0.001868151,0.0001304705,0.002725976],"genre_scores_gemma":[0.9908535,0.002381159,0.0008345859,0.0008824568,0.0001623849,0.001325399,0.001705701,0.00002584938,0.001828884],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004230346,"threshold_uncertainty_score":0.01415193,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05395153373911955,"score_gpt":0.4301635303496723,"score_spread":0.3762119966105528,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}